Publication: Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: analysis of 956 patients
dc.contributor.coauthor | Topkan, Erkan | |
dc.contributor.coauthor | Özdemir, Yurday | |
dc.contributor.coauthor | Küçük, Ahmet | |
dc.contributor.coauthor | Besen, Ali Ayberk | |
dc.contributor.coauthor | Mertsoylu, Hüseyin | |
dc.contributor.coauthor | Sezer, Ahmet | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Selek, Uğur | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T13:08:22Z | |
dc.date.issued | 2019 | |
dc.description.abstract | Background: to investigate the detrimental effects of prolonged overall radiotherapy duration (ORTD) on survival outcomes of stage IIIB/C NSCLC patients treated with concurrent chemoradiotherapy (C-CRT) Methods: the study cohort consisted of 956 patients who underwent C-CRT for stage IIIB/C NSCLC. Primary endpoint was the association between the ORTD and overall survival (OS) with locoregional progression-free survival (LRPFS) and PFS comprising the secondary endpoints. Receiver operating characteristic (ROC) curve analysis was utilized for accessibility of the cut-off that interacts with survival outcomes. Multivariate Cox model was utilized to identify the independent associates of survival outcomes. Results: the ROC curve analysis exhibited significance at 49 days of ORTD cut-off that dichotomized patients into ORTD<50 versus ORTD50 days groups for OS [area under the curve (AUC): 82.8%; sensitivity: 81.1%; specificity: 74.8%], LRPFS (AUC: 91.9%; sensitivity: 90.6%; specificity: 76.3%), and PFS (AUC: 76.1%; sensitivity: 72.4%; specificity: 68.2%), respectively. Accordingly, ORTD50 days group had significantly shorter median OS (P<0.001), LRPFS (P<0.001), and PFS (P<0.001); and 10-year actuarial locoregional control (P<0.001) and distant metastases-free (P<0.011) rates than the ORTD<50 days group. The ORTD retained its significant association with survival outcomes at multivariate analyses independent of the other favorable covariates (p<0.001, for OS, LRPFS, and PFS): Stage IIIB disease (versus IIIC), lymph node bulk <2 cm (versus 2 cm), and 2–3 chemotherapy cycles (versus 1). The higher sensitivity for LRPFS (90.6%) than PFS (72.4%) on ROC curve analysis suggested the prolonged ORTD-induced decrements in locoregional control rates as the major cause of the poor survival outcomes. Conclusions: longer ORTD beyond 50 days was associated with significantly poorer OS, LRPFS and PFS outcomes, where reduced locoregional control rates appeared to be the main causative. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 7 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.version | Publisher version | |
dc.description.volume | 14 | |
dc.identifier.doi | 10.1371/journal.pone.0218627 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR01641 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85069855309 | |
dc.identifier.uri | https://doi.org/10.1371/journal.pone.0218627 | |
dc.identifier.wos | 484974100008 | |
dc.keywords | Treatment time | |
dc.keywords | Radiation-therapy | |
dc.keywords | Local-control | |
dc.keywords | Phase-III | |
dc.keywords | Sequential chemoradiotherapy | |
dc.keywords | Retrospective analysis | |
dc.keywords | Thoracic radiotherapy | |
dc.keywords | Chemotherapy worth | |
dc.keywords | Advanced head | |
dc.keywords | Cancer | |
dc.language.iso | eng | |
dc.publisher | Public Library of Science | |
dc.relation.grantno | NA | |
dc.relation.ispartof | PLOS One | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8264 | |
dc.subject | Science and technology | |
dc.title | Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: analysis of 956 patients | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Selek, Uğur | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |
Files
Original bundle
1 - 1 of 1